Infection
Glycopeptides (vancomycin)
Large antibiotics that block cell wall synthesis at an earlier step than β-lactams; the main treatment for MRSA, including endocarditis, and given by mouth for Clostridioides difficile.
Mechanism of action
- Vancomycin binds the D-alanyl-D-alanine end of cell wall precursors.
- This blocks their transfer into the growing peptidoglycan and its cross-linking.
- It is bactericidal against gram-positive bacteria, including MRSA, but too large to cross the outer membrane of gram-negative bacteria.
- Enterococci can resist by changing the target to D-alanyl-D-lactate (VRE).
Molecular targets
- D-Ala-D-Ala terminus of peptidoglycan precursors: Binds and blocks
Drugs in Glycopeptides (vancomycin)
Glycopeptides
- Vancomycin (Intravenous; by mouth only for C. difficile, since it is not absorbed.)
- Teicoplanin
Lipoglycopeptides
- Telavancin and dalbavancin
Therapeutic uses
- Infective endocarditis due to MRSA, or in penicillin allergy
- Serious MRSA infections
- Clostridioides difficile colitis (by mouth)
Diseases it treats
Pharmacokinetics
- Excreted by the kidney; blood levels are monitored.
Adverse effects
- Infusion reaction with flushing ("red man" or vancomycin flushing syndrome) when infused quickly
- Nephrotoxicity, more with aminoglycosides
- Ototoxicity
Contraindications by condition
- Kidney impairment (Use with care): It accumulates and can damage the kidney further.
- Taking aminoglycosides or loop diuretics (Use with care): Their kidney and ear toxicity add up.
Written from
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 29, Cell Wall Inhibitors, Vancomycin
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 43, Beta-Lactam & Other Cell Wall- & Membrane-Active Antibiotics, Glycopeptide antibiotics
Educational reference. Not medical advice, diagnosis or treatment.